Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study.
Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study.
复制标题
DOI：
10.1093/ckj/sfab248
复制
发表时间：
2022-03
影响因子：
4.6
通讯作者：
Gonzalez-Parra E
中科院分区：
文献类型：
--
作者：
Carriazo S;Mas-Fontao S;Seghers C;Cano J;Goma E;Avello A;Ortiz A;Gonzalez-Parra E
在易患严重COVID-19的合并症中，透析导致2019冠状病毒病（COVID-19）死亡的风险最高。然而，COVID-19相关死亡率的报告通常是指首次住院期间或诊断后第一个月的死亡率。在一项前瞻性、观察性研究中，我们分析了56名在第一波大流行期间感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的血液透析（HD）患者的长期（1年随访）血清学和临床结局。COVID-19是通过阳性聚合酶链反应（PCR）检测（n = 37）或通过抗SARS-CoV-2抗体的产生（n = 19）诊断的。经过1年以上的随访，在第一波大流行期间感染SARS-CoV-2的HD患者中有35.7%死亡，其中6例（11%）在首次入院时死亡，14例（25%）在随后的几个月内死亡，主要是在诊断后的前3个月内。总体而言，30%的患者死于血管原因，40%死于呼吸道原因。在校正分析中，SARS-CoV-2 PCR检测阳性诊断{风险比[HR] 5.18 [四分位距（IQR）1.30-20.65]，P = 0.020}，基线C反应蛋白水平较高[HR 1.10（IQR 1.03-1.16），P = 0.002]和较低的血红蛋白水平[HR 0.62（IQR 0.45-0.86），P = 0.005]与较高的1年死亡率相关。144名未患COVID-19的患者在12个月内的死亡率为21人（14.6%）[COVID-19患者死亡的HR为3.00（IQR 1.62-5.53），对数秩P = 0.00023]。在第一年，具有抗SARS-CoV-2免疫球蛋白G（IgG）的患者百分比从最初的36/49（73.4%）下降到6个月时的27/44（61.3%）和12个月时的14/36（38.8%）。COVID-19 HD患者的高死亡率并不局限于最初的住院治疗。将COVID-19死亡定义为COVID-19诊断后3个月内发生的死亡，可能更好地代表COVID-19的负担。在HD患者中，抗SARS-CoV-2 IgG应答是次优的且短暂的。
Dialysis confers the highest risk of coronavirus disease 2019 (COVID-19) death among comorbidities predisposing to severe COVID-19. However, reports of COVID-19-associated mortality frequently refer to mortality during the initial hospitalization or first month after diagnosis. In a prospective, observational study, we analysed the long-term (1-year follow-up) serological and clinical outcomes of 56 haemodialysis (HD) patients who were infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first pandemic wave. COVID-19 was diagnosed by a positive polymerase chain reaction (PCR) test (n = 37) or by the development of anti-SARS-CoV-2 antibodies (n = 19). After >1 year of follow-up, 35.7% of HD patients infected by SARS-CoV-2 during the first pandemic wave had died, 6 (11%) during the initial admission and 14 (25%) in the following months, mainly within the first 3 months after diagnosis. Overall, 30% of patients died from vascular causes and 40% from respiratory causes. In adjusted analysis, a positive SARS-CoV-2 PCR test for diagnosis {hazard ratio [HR] 5.18 [interquartile range (IQR) 1.30–20.65], P = 0.020}, higher baseline C-reactive protein levels [HR 1.10 (IQR 1.03–1.16), P = 0.002] and lower haemoglobin levels [HR 0.62 (IQR 0.45–0.86), P = 0.005] were associated with higher 1-year mortality. Mortality in the 144 patients who did not have COVID-19 was 21 (14.6%) over 12 months [HR of death for COVID-19 patients 3.00 (IQR 1.62–5.53), log-rank P = 0.00023]. Over the first year, the percentage of patients having anti-SARS-CoV-2 immunoglobulin G (IgG) decreased from 36/49 (73.4%) initially to 27/44 (61.3%) at 6 months and 14/36 (38.8%) at 12 months. The high mortality of HD patients with COVID-19 is not limited to the initial hospitalization. Defining COVID-19 deaths as those occurring within 3 months of a COVID-19 diagnosis may better represent the burden of COVID-19. In HD patients, the anti-SARS-CoV-2 IgG response was suboptimal and short-lived.
登录
查看更多内容
影响因子：
13.6
作者：
Babitt, Jodie L.;Lin, Herbert Y.
通讯作者：
Lin, Herbert Y.
影响因子：
2.6
作者：
Fernandez-Prado, Raul;Pena-Esparragoza, Jessy Korina;Gonzalez-Parra, Emilio
通讯作者：
Gonzalez-Parra, Emilio
影响因子：
19.6
作者：
Massry, SG;Smogorzewski, M
通讯作者：
Smogorzewski, M
DOI：
10.1016/j.ajem.2021.03.083
发表时间：
2021-10
期刊：
The American journal of emergency medicine
影响因子：
--
作者：
Oh SM;Skendelas JP;Macdonald E;Bergamini M;Goel S;Choi J;Segal KR;Vivek K;Nair S;Leff J
通讯作者：
Leff J
DOI：
10.1016/j.rccl.2020.11.004
发表时间：
2020-11-17
期刊：
Rec. Cardioclinics
影响因子：
--
作者：
García-Guimaraes M;Mojón D;Calvo A;Izquierdo A;Belarte-Tornero L;Salvatella N;Llagostera M;Negrete A;Mas-Stachurska A;Ruiz S;Valdivielso S;Ribas N;Marrugat J;Farré N;Vaquerizo B
通讯作者：
Vaquerizo B